儿童鼻咽癌临床治疗研究

廖伟伟; 唐锁勤; 刘英; 冯晨

doi:10.7499/j.issn.1008-8830.2013.04.007

PDF(893 KB)

中国当代儿科杂志 ›› 2013, Vol. 15 ›› Issue (4) : 273-276. DOI: 10.7499/j.issn.1008-8830.2013.04.007

论著·临床研究

儿童鼻咽癌临床治疗研究

廖伟伟，唐锁勤，刘英，冯晨

作者信息 +

Treatment of nasopharyngeal carcinoma in children

LIAO Wei-Wei, TANG Suo-Qin, LIU Ying, FENG Chen

Author information +

文章历史 +

摘要

目的：探讨ARAR0331方案对儿童鼻咽癌的治疗效果。方法：回顾性分析2004年5月至2012年5月收治的8例鼻咽癌患儿的临床资料。8例患儿中，男6例，女2例，发病年龄3~13岁；ⅡA期、ⅣA期各1例，Ⅲ期6例。1例（Ⅲ期）采用以EAP、BEP和EA为主的化疗联合放疗的方案，7例采用美国儿童肿瘤协作组（COG）ARAR0331治疗方案。结果：采用以EAP、BEP和EA为主的化疗联合放疗治疗的这例患儿，化疗过程中出现多发骨转移。ARAR0331方案治疗的7例患儿中，4例处于完全缓解，2例处于部分缓解。目前7例患儿均存活，生存率为100%，生存期为8~75个月。ARAR0331治疗并发症主要包括放射性皮炎、口咽黏膜炎及胃肠道反应，未发现远期并发症。结论：ARAR0331方案为有效、安全的治疗儿童鼻咽癌的方法，但需积累更多病例进一步证实。

Abstract

OBJECTIVE: To evaluate the clinical efficacy of the ARAR0331 protocol for treatment of childhood nasopharyngeal carcinoma. METHODS: The clinical data of eight children with nasopharyngeal carcinoma between May 2004 and May 2012 were retrospectively studied. The eight patients included six boys and two girls, and the onset age was between 3 and 13 years. Six patients were in AJCC Stage Ⅲ, one was in StageⅡA and one was in Stage ⅣA. One patient had been treated with combined radiotherapy and chemotherapy which mainly included EAP, BEP and EA. The other seven patients had been treated with the ARAR0331 protocol provided by the America Children′s Oncology Group (COG). RESULTS: The patient who had been treated with combined radiotherapy and chemotherapy developed multiple bony metastasis during the chemotherapeutic period. Four out of seven patients who had been treated with ARAR0331 protocol achieved complete remission, and two achieved partial remission. The seven patients were followed-up from 8 to 75 months and the survival rate was 100%. The ARAR0331 protocol treatment-related complications included radiodermatitis, mucocitis and nausea. Late toxicity was not found. CONCLUSIONS: Based on the limited cases, ARAR0331 protocol appears to be effective and safe for childhood nasopharyngeal carcinoma.

导出引用

廖伟伟，唐锁勤，刘英，冯晨. 儿童鼻咽癌临床治疗研究[J]. 中国当代儿科杂志. 2013, 15(4): 273-276 https://doi.org/10.7499/j.issn.1008-8830.2013.04.007

LIAO Wei-Wei, TANG Suo-Qin, LIU Ying, FENG Chen. Treatment of nasopharyngeal carcinoma in children[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(4): 273-276 https://doi.org/10.7499/j.issn.1008-8830.2013.04.007

参考文献

［1］黄选兆，汪吉宝，孔维佳. 实用耳鼻咽喉头颈部外科学［M］. 第2版. 北京：人民卫生出版社，2009：342-347.

［2］张伟军，王兆武，王继群，张涛，山艳春. 45例儿童及青少年鼻咽癌的放射治疗及预后分析［J］．中华放射医学与防护杂志，2004，24(1)：55-56.

［3］刘菊英，魏宝清，陆进成，朱军，张宜勤. 145例儿童及青少年鼻咽癌临床与疗效分析［J］．中华放射肿瘤学杂志，2003，12(4)：234-238.

［4］洪继东，廖遇平，袁君，魏瑞，王学伟，毛海娇. 44例儿童青少年鼻咽癌临床和预后分析［J］. 中南大学学报医学版，2008，33(8)：723-726.

［5］范长根，韩亚骞，陈艳平，吴湘玮.同步放化疗治疗72 例儿童青少年鼻咽癌临床疗效［J］．现代肿瘤医学，2011，19（6）：1107-1109.

［6］Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. AJCC cancer staging manual［M］. 5th ed. Philadelphia: Lippincott-Raven, 1997: 31-39.

［7］Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH. Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1-1)［J］. Eur J Cancer, 2009, 45(2): 228-247.

［8］Brennan B. Nasopharyngeal carcinoma［J/OL］. Orphanet J Rare Dis, 2006, 1: 23.

［9］Cheuk DKL, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ, et al, Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma［J］. Cancer, 2011, 117(1): 197-206.

［10］Haimi M, Arush MW, Bar-Sela G, Gez E,Bernstein Z,Postovsky S,et al. Nasopharyngeal carcinoma in the pediatric age group The northern Isreal (Rambam) medical center experience,1989-2004［J］. J Pediatr Hematol Oncol, 2005, 27(10): 510-516.

［11］Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG［J］. Cancer, 2012, 118(19): 4892-4900.

［12］Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma［J］. J Immunother, 2010, 33(9): 983-990.

［13］Chen C, Wang FH, Wang ZQ, An X, Luo HY, Zhang L, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy［J］. Oral Oncol, 2012, 48(11): 1146-1151.